GATS trial

A phase II study with CD20-positive non-Hodgkin's lymphoma treated with shorter duration of infusion of GA101(RO5072759)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222796

Enrollment

Registered

2015-03-17

Start date

2015-04-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with CD20-positive non-Hodgkin's lymphoma (diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL))

Interventions

investigational material(s) Generic name etc : Obinutuzumab (RO5072759/GA101) INN of investigational material : Obinutuzumab Therapeutic category code : 429 Other antitumor agents Dosage and Administr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: *Previously untreated CD20-positive B cell NHL (DLBCL,FL,MZL) *Sufficient major organ function *Performance status (PS) of 0-2

Exclusion criteria

Exclusion criteria: *History of severe allergic or anaphylactic reactions to test drug or its component *Prior use of an anti-CD20 antibody *Current or previous history of clinically significant disease *Positive test results or known active viral infection including HBV,HCV,and HTLV-1 *Women who are pregnant, lactating. Women who get positive results from pregnancy tests.

Design outcomes

Primary

Measure	Time frame
safety pharmacokinetics Tolerability, Pharmacokinetics Assessment and observations	—

Secondary

Measure	Time frame
safety efficacy Safety, Anti-tumour activity Assessment and observations	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026